Statistics for Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma
Total visits
| views | |
|---|---|
| Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma | 50 |
Total visits per month
| views | |
|---|---|
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:9cb03ce9-d5bc-471c-9dff-432a72392dd4 | 51 |
| nihms-1541537.pdf | 37 |
| java.util.UUID:03d2ad63-4187-4044-a69c-b0752c5358fe | 2 |
Top country views
| views | |
|---|---|
| United States | 46 |
Top city views
| views | |
|---|---|
| Wilmington | 41 |
| Ann Arbor | 1 |
| Cambridge | 1 |
| Lake Mary | 1 |